Tailoring rituximab treatment among patients with pemphigus based on the presence of predictors of early relapse reduced relapse rates at 12 months.

Therefore, the propensity of the malignancy to mutate is critically important for the risk of relapse. Although there is a slower pace of relapse for CML, the general pace of relapse remains very ...